Chugai Pharmabody
Chugai Pharmabody Research (CPR) is dedicated to innovative antibody research and drug discovery, collaborating with academia, industry, and government to develop therapeutics that address unmet medical needs. The company actively participates in scientific symposia, supports education, and celebrates milestones such as anniversaries and scientific events, emphasizing continuous improvement and fostering scientific progress. CPR also engages in outreach activities such as science education programs, industry collaborations, and community events to promote science and technology.
Industries
Nr. of Employees
medium (51-250)
Chugai Pharmabody
Products
T‑cell engaging bispecific antibody platform
A bispecific antibody platform designed to engage T cells and improve tumor cell killing in preclinical models, suitable for lead optimization in immuno‑oncology programs.
Tumor‑selective agonist antibody modality
An antibody modality engineered to exert agonist activity selectively within tumor microenvironments activated by pathological signals to limit systemic on‑target toxicity.
Early‑stage antibody production and screening platform
A platform addressing early discovery antibody production bottlenecks to increase throughput for screening and reagent supply.
T‑cell engaging bispecific antibody platform
A bispecific antibody platform designed to engage T cells and improve tumor cell killing in preclinical models, suitable for lead optimization in immuno‑oncology programs.
Tumor‑selective agonist antibody modality
An antibody modality engineered to exert agonist activity selectively within tumor microenvironments activated by pathological signals to limit systemic on‑target toxicity.
Early‑stage antibody production and screening platform
A platform addressing early discovery antibody production bottlenecks to increase throughput for screening and reagent supply.
Services
Antibody discovery and engineering
Design and engineering of antibody formats (including recycling/sweeping mechanisms and bispecific constructs) to support discovery and lead generation.
Lead optimization and preclinical development
Protein engineering, in vitro characterization, and in vivo efficacy testing to advance preclinical candidates toward clinical entry.
Recombinant protein production and purification
Expression and purification workflows for antibodies and other therapeutic proteins to supply discovery, screening, and structural studies.
Laboratory automation and data management services
Implementation of automated laboratory workflows and centralized data pipelines to improve throughput and reproducibility in discovery projects.
Translational collaborations and educational outreach
Partnerships with academic institutes and research agencies, including symposia, guest lectures, lab tours and educator engagement to facilitate translational research and science education.
Antibody discovery and engineering
Design and engineering of antibody formats (including recycling/sweeping mechanisms and bispecific constructs) to support discovery and lead generation.
Lead optimization and preclinical development
Protein engineering, in vitro characterization, and in vivo efficacy testing to advance preclinical candidates toward clinical entry.
Recombinant protein production and purification
Expression and purification workflows for antibodies and other therapeutic proteins to supply discovery, screening, and structural studies.
Laboratory automation and data management services
Implementation of automated laboratory workflows and centralized data pipelines to improve throughput and reproducibility in discovery projects.
Translational collaborations and educational outreach
Partnerships with academic institutes and research agencies, including symposia, guest lectures, lab tours and educator engagement to facilitate translational research and science education.
Expertise Areas
- Antibody engineering
- Bispecific antibody development
- Tumor microenvironment‑activated modalities
- Recombinant protein production
Key Technologies
- Antibody engineering
- Bispecific antibody platforms
- T‑cell engaging bispecific formats
- Tumor microenvironment‑activated design